{"address1": "Wallstrasse 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "fax": "49 89 2153 90351", "website": "https://www.atai.life", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 70000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder & CEO", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 793650, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 494232, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 42, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sahil V. Kirpekar M.D.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.36, "open": 1.36, "dayLow": 1.22, "dayHigh": 1.375, "regularMarketPreviousClose": 1.36, "regularMarketOpen": 1.36, "regularMarketDayLow": 1.22, "regularMarketDayHigh": 1.375, "payoutRatio": 0.0, "beta": 1.186, "forwardPE": -1.8235294, "volume": 2918505, "regularMarketVolume": 2918505, "averageVolume": 2852666, "averageVolume10days": 1890750, "averageDailyVolume10Day": 1890750, "bid": 1.23, "ask": 1.27, "bidSize": 1, "askSize": 2, "marketCap": 245899440, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 2.85, "priceToSalesTrailing12Months": 798.3748, "fiftyDayAverage": 1.7021, "twoHundredDayAverage": 1.435975, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 210733008, "profitMargins": 0.0, "floatShares": 154550136, "sharesOutstanding": 198306000, "sharesShort": 10403773, "sharesShortPriorMonth": 11160861, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0525, "heldPercentInsiders": 0.085769996, "heldPercentInstitutions": 0.29185, "shortRatio": 3.61, "shortPercentOfFloat": 0.0656, "impliedSharesOutstanding": 213560992, "bookValue": 0.692, "priceToBook": 1.7919075, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -149268992, "trailingEps": -0.93, "forwardEps": -0.68, "enterpriseToRevenue": 684.198, "enterpriseToEbitda": -2.122, "52WeekChange": -0.48117155, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.24, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 4, "totalCash": 62330000, "totalCashPerShare": 0.314, "ebitda": -99299000, "totalDebt": 26906000, "quickRatio": 2.552, "currentRatio": 3.211, "totalRevenue": 308000, "debtToEquity": 23.085, "revenuePerShare": 0.002, "returnOnAssets": -0.27539, "returnOnEquity": -0.8316, "grossProfits": 308000, "freeCashflow": -54122000, "operatingCashflow": -82437000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": 5869.2, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Atai Life Sciences N.V.", "shortName": "ATAI Life Sciences N.V.", "regularMarketChangePercent": -8.823529, "regularMarketPrice": 1.24, "marketState": "PRE", "regularMarketChange": -0.120000005, "regularMarketDayRange": "1.22 - 1.375", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2852666, "fiftyTwoWeekLowChange": 0.21000004, "fiftyTwoWeekLowChangePercent": 0.20388354, "fiftyTwoWeekRange": "1.03 - 2.85", "fiftyTwoWeekHighChange": -1.6099999, "fiftyTwoWeekHighChangePercent": -0.56491226, "fiftyTwoWeekChangePercent": -48.117153, "earningsTimestamp": 1742212801, "earningsTimestampStart": 1747133940, "earningsTimestampEnd": 1747656000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.93, "epsForward": -0.68, "epsCurrentYear": -0.82667, "priceEpsCurrentYear": -1.4999939, "fiftyDayAverageChange": -0.46210003, "fiftyDayAverageChangePercent": -0.27148816, "twoHundredDayAverageChange": -0.19597495, "twoHundredDayAverageChangePercent": -0.13647519, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "corporateActions": [], "regularMarketTime": 1743537602, "exchange": "NGM", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Atai Life Sciences", "trailingPegRatio": null}